Magnesium L-Threonate

Magnesium L-threonate is the supplement industry’s favorite example of how compelling animal data can be translated into human marketing long before human evidence justifies the claims. The rat studies are genuinely interesting. The human studies are small, industry-funded, and preliminary. The gap between the two is what honest framing must address.

The origin story is scientific. Slutsky et al. (2010) at MIT developed magnesium L-threonate specifically to test whether increasing brain magnesium could enhance synaptic plasticity. In rats, the compound increased cerebrospinal fluid magnesium concentration, raised synaptic density in the hippocampus, and improved performance on multiple learning and memory tasks. The mechanism involved upregulation of NR2B-containing NMDA receptors and enhancement of long-term potentiation — the cellular basis of learning.

The translation to humans has been slower and less dramatic. Liu et al. (2016) conducted a randomized, double-blind trial of MMFS-01 (magnesium L-threonate) in 44 older adults with self-reported cognitive impairment. After 12 weeks, the treatment group showed improvements in executive function and working memory compared to placebo. The effect sizes were modest, the sample was small, and the study was funded by the patent holder. Zhang et al. (2022) tested a Magtein-based formula in 109 healthy Chinese adults and found improvements in cognitive function tests after 30 days — again, small, short, and industry-associated.

The most overstated claim in marketing is that threonate is “the only magnesium that crosses the blood-brain barrier.” This is pharmacologically false. The brain actively regulates magnesium via TRPM6 and TRPM7 ion channels, and all bioavailable magnesium forms raise serum magnesium, which the brain then accesses. The threonate anion may facilitate transport in rodent models, but no human study has demonstrated superior brain delivery of threonate versus glycinate or citrate at equivalent elemental magnesium doses. The rat-to-human extrapolation remains unverified.

The honest framing: magnesium L-threonate is a plausible but unproven cognitive intervention. The animal work is high-quality and suggests a genuine mechanistic pathway. The human work is too small and too short to support strong claims. It is not a treatment for dementia. It is not proven superior to other magnesium forms for brain health. If you choose to try it, do so with realistic expectations and understand that 2,000mg of threonate provides only ~144mg elemental magnesium — you will need dietary magnesium or another supplement to meet the ~400mg RDA.

Practical guidance: 1,000-2,000mg daily in divided doses. Take with meals. Do not rely on threonate as your sole magnesium source. If cognitive concerns are significant, see a physician — memory impairment can signal B12 deficiency, thyroid dysfunction, sleep apnea, or other treatable conditions that magnesium will not address.